Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemo-attractant Receptor-Homologous Molecule on T-helper-2 Cells (CRTH2), also known as GPR44 or DP2, is a G protein-coupled receptor primarily expressed on Th2 cells, eosinophils, basophils and a subset of monocytes. It is activated by prostaglandin D2 (PGD2), which is released during allergic responses. CRTH2 mediates chemotaxis of these cell types and promotes the production of Th2-associated cytokines (IL-4, IL-5, IL-13), playing a crucial role in the pathogenesis of asthma, allergic rhinitis, and other type 2 inflammatory disorders. Antagonists of CRTH2 are being explored as potential therapeutic agents for these conditions.
Antagonism of CRTH2 receptor
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chemo-attractant Receptor-Homologous Molecule on T-helper-2 Cells (CRTH2).